Consensus Telix Pharmaceuticals Limited

Stocks

TLX

AU000000TLX2

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 07:12:56 12/06/2026 BST			5-day change	1st Jan Change
13.60 ^AUD	+0.97%		+2.18%	+21.43%

06-03	Telix Pharmaceuticals, United Imaging Healthcare Sign MOU for US Theranostics Collaboration; Shares Down 3%	MT
06-02	Telix Pharmaceuticals, United Imaging Healthcare Sign MOU for US Theranostics Collaboration	MT

Evolution of the Average Target: Telix Pharmaceuticals Limited

Evolution of the Target Price: Telix Pharmaceuticals Limited

Changes in Analyst Recommendations: Telix Pharmaceuticals Limited

f1ce9ebb4637.iyQMfH8sMT3hmrQdU17ItFliuo3XEHkXb_fG_elGCMk.xm04GDh0Z2ek8NtZOxGi9w0Oz8eAeAh6O56zmacJZ_7ZQUMOPVZuENDThA~ac1981f10f90f65a1f1854e3e7271d0c

Analysts' recommendations: Telix Pharmaceuticals Limited

04-16	Telix Enters Attractive Market With Late-Stage Brain Cancer Drug Trial in US, Jefferies Says	MT
04-13	Telix Pharmaceuticals' Pipeline Validated by Regeneron Deal, Citi Says	MT
04-08	Jarden Adjusts Telix Pharmaceuticals's Price Target to AU$21.80 from AU$21, Keeps at Buy	MT
04-07	Telix Pharmaceuticals US PSMA PET Sales Gain Traction, Seen to Grow Market Share, Says Jefferies	MT
03-02	Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says	MT
01-21	Telix Pharmaceuticals Poised for Growth With Strong Illuccix Sales, Gozellix Launch, Jefferies Says	MT
01-13	Telix Pharmaceuticals Reaffirms Guidance Amid Imminent Drug Launches in US, Says Jefferies	MT
12-11	Telix Pharmaceuticals Poised for 'Solid' Q4 Revenue Growth, Jefferies Says	MT
11-12	Alerts from law firm on Telix pharmaceuticals withdrawn	RE
11-12	Telix Reports Positive Results from TLX250-CDx Imaging Trial in Triple Negative Breast Cancer Patients, Shares Fall 3%	MT
07/10/25	Barrenjoey Markets Starts Telix Pharmaceuticals at Overweight with AU$22 Price Target	MT
25/09/25	Telix Pharmaceuticals' Gozellix Expected to See Strong Sales Growth After TPT Status Grant, Jarden Research Says	MT
23/09/25	UBS Adjusts Price Target on Telix Pharmaceuticals to $20 From $23, Maintains Buy Rating	MT
19/09/25	Telix Pharmaceuticals Shows Strong Growth Potential With Blockbuster Drug Prospect, Citi Says	MT
18/09/25	Citigroup Initiates Telix Pharmaceuticals at Buy With $22 Price Target	MT
21/08/25	Telix Pharmaceuticals' Profitability Expected to Rebound, Wedbush Says	MT
06/08/25	Jarden Research Adjusts Telix Pharmaceuticals' Price Target to AU$27.61 from AU$29.14; Keeps at Buy	MT
03/07/25	HC Wainwright Initiates Telix Pharmaceuticals at Buy With $23 Price Target	MT
05/06/25	Wedbush Initiates Telix Pharmaceuticals at Outperform With $22 Price Target	MT
27/01/25	UBS Adjusts Price Target on Telix Pharmaceuticals to $22 From $21, Keeps Buy Rating	MT
30/09/24	Telix Pharmaceuticals Has Long-term Opportunity to Become Isotope Manufacturer After Acquisition, Says Jefferies	MT
23/08/24	Bell Potter Downgrades Telix Pharmaceuticals to Hold From Buy; Price Target is AU$21.30	MT
30/07/24	Jarden Research Adjusts Telix Pharmaceuticals' Price Target to AU$22.55 From AU$22.49, Keeps at Buy	MT
03/06/24	Jarden Research Adjusts Telix Pharmaceuticals’ Price Target to AU$16.62 From AU$13.94, Keeps at Buy	MT
30/04/24	Bell Potter Downgrades Telix Pharmaceuticals to Hold from Buy, Price Target is AU$14.50	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	TELIX PHARMACEUTICALS LIMITED					+71.49%
	LONZA GROUP AG					+35.33%
	REVOLUTION MEDICINES, INC.					+21.72%
	IQVIA HOLDINGS INC.					+25.07%
	BEONE MEDICINES AG					+55.91%
	CELLTRION, INC.					+46.2%
	MEDPACE HOLDINGS, INC.					-5.24%
	EUROFINS SCIENTIFIC SE					+10.62%
	IONIS PHARMACEUTICALS, INC.					+39.43%
	Average					+33.39%
	Weighted average by Cap.					+32.50%